menu search

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients – – Progression-free survival of 5.6 months in median third-line colorectal cancer patients without bevacizumab – – Promising safety profile in combination with FOLFIRI and bevacizumab – – Randomized combination trial in second-line colorectal […] The post IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Developm... Read More
Posted: Jun 2 2023, 21:30
Author Name: forextv
Views: 102573

Search within

Pages Search Results: